{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:00:56Z","timestamp":1790740856787,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bone.2026.118053","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T14:17:34Z","timestamp":1786889854000},"page":"118053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Three Generations of X-Linked Hypophosphataemia: The Inter-generational Impact of Burosumab Across the Lifespan"],"prefix":"10.1016","volume":"213","author":[{"given":"Maria","family":"Bilal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shejil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myra","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"58","key":"10.1016\/j.bone.2026.118053_bb0005","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bone.2026.118053_bb0010","series-title":"GeneReviews\u00ae [Internet]","article-title":"X-Linked Hypophosphatemia","author":"Laurent","year":"1993"},{"key":"10.1016\/j.bone.2026.118053_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.688309","article-title":"X-linked hypophosphatemic rickets: multisystemic disorder in children requiring multidisciplinary management","volume":"12","author":"Baroncelli","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"8","key":"10.1016\/j.bone.2026.118053_bb0020","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1210\/clinem\/dgaf170","article-title":"X-linked hypophosphatemia management in adults: an international working group clinical practice guideline","volume":"110","author":"Khan","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.bone.2026.118053_bb0025","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"Clinician\u2019s guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter TO","year":"2011","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2026.118053_bb0030","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab070","article-title":"Patient-Reported Complications, Symptoms, and Experiences of Living With X-Linked Hypophosphatemia Across the Life-Course","volume":"5","author":"Cheung","year":"2021","journal-title":"J Endocr Soc."},{"issue":"3","key":"10.1016\/j.bone.2026.118053_bb0035","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms","volume":"174","author":"Che","year":"2016","journal-title":"Eur. J. Endocrinol."},{"issue":"7","key":"10.1016\/j.bone.2026.118053_bb0040","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1210\/clinem\/dgaf093","article-title":"X-linked hypophosphatemia management in children: an international working group clinical practice guideline","volume":"110","author":"Ali","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"21","key":"10.1016\/j.bone.2026.118053_bb0045","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bone.2026.118053_bb0050","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2026.118053_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001714","article-title":"Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension","volume":"7","author":"Briot","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.bone.2026.118053_bb0060","article-title":"PRO152 confirmatory psychometric validation of the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) in adult X-linked hypophosphatemia (XLH)","volume":"22","author":"Skrinar","year":"2019","journal-title":"Value Health"},{"issue":"10189","key":"10.1016\/j.bone.2026.118053_bb0065","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bone.2026.118053_bb0070","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/jbmr\/zjaf063","article-title":"Real-world effectiveness of burosumab vs oral phosphate and active vitamin D in adults with X-linked hypophosphatemia","volume":"40","author":"Florenzano","year":"2025","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2026.118053_bb0075","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00223-025-01433-2","article-title":"Real-world effectiveness of burosumab in adults with X-linked hypophosphataemia (XLH) in the UK","volume":"116","author":"Bubbear","year":"2025","journal-title":"Calcif. Tissue Int."},{"issue":"Supplement_5","key":"10.1016\/j.bone.2026.118053_bb0080","doi-asserted-by":"crossref","first-page":"v39","DOI":"10.1093\/jbmrpl\/ziae132","article-title":"Burosumab in adults with X-linked hypophosphatemia: real-world experience from a retrospective study in Sydney","volume":"9","author":"Kumar","year":"2025","journal-title":"JBMR Plus."},{"issue":"8","key":"10.1016\/j.bone.2026.118053_bb0085","doi-asserted-by":"crossref","DOI":"10.1093\/jbmrpl\/ziae079","article-title":"Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study","volume":"8","author":"Michigami","year":"2024","journal-title":"JBMR Plus."},{"issue":"2","key":"10.1016\/j.bone.2026.118053_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.2387","article-title":"Real-world data of Brazilian adults with X-linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts","volume":"12","author":"Vaisbich","year":"2024","journal-title":"Mol. Genet. Genomic Med."},{"issue":"1","key":"10.1016\/j.bone.2026.118053_bb0095","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13023-021-01729-0","article-title":"Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population","volume":"16","author":"Rodr\u00edguez-Rubio","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.bone.2026.118053_bb0100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41439-020-0095-1","article-title":"Phenotypes of a family with XLH with a novel PHEX mutation","volume":"7","author":"Yamamoto","year":"2020","journal-title":"Hum Genome Var."},{"key":"10.1016\/j.bone.2026.118053_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.699767","article-title":"Genotype and phenotype analysis in X-linked hypophosphatemia","volume":"9","author":"Park","year":"2021","journal-title":"Front. Pediatr."},{"issue":"1","key":"10.1016\/j.bone.2026.118053_bb0110","article-title":"Clinical, radiographic, and molecular analysis of patients with X-linked hypophosphatemic rickets: looking for phenotype\u2013genotype correlation","volume":"15","author":"Olivas-Valdez","year":"2025","journal-title":"Diagnostics (Basel, Switzerland)"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226002796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226002796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:38:05Z","timestamp":1790739485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328226002796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":22,"alternative-id":["S8756328226002796"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2026.118053","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three Generations of X-Linked Hypophosphataemia: The Inter-generational Impact of Burosumab Across the Lifespan","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2026.118053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118053"}}